Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Viridian Therapeutics Q4 2023 GAAP EPS $(1.35) Misses $(0.97) Estimate, Sales $72.00K Miss $159.60K Estimate

Author: Benzinga Newsdesk | February 27, 2024 06:14pm
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(1.35) per share which missed the analyst consensus estimate of $(0.97) by 39.18 percent. The company reported quarterly sales of $72.00 thousand which missed the analyst consensus estimate of $159.60 thousand by 54.89 percent. This is a 31.43 percent decrease over sales of $105.00 thousand the same period last year.

Posted In: VRDN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist